DTIL — Precision Biosciences Share News
0.000.00%
Last trade - 00:00- $183.27m
- $118.15m
- $34.26m
Precision Bio rises on positive FDA feedback for hepatitis B therapy study
Brief: Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV
Brief: Precision Bio Receives Initial $7.5 Mln Cash Payment And Equity Investment From TG Therapeutics For Azel-Cel
U.S. STOCKS ON THE MOVE-ResMed, Revvity, Acuity Brands
U.S. STOCKS ON THE MOVE-Albemarle, Illumina, Eversource Energy
U.S. STOCKS ON THE MOVE-CrowdStrike, Precision BioSciences, Tilray Brands
Precision BioSciences rises on license deal to develop cancer therapy
Brief: Precision Biosciences Completes License Deal With TG Therapeutics For Cell Therapy Azer-Cel
Brief: Tg Therapeutics Announces Global License Agreement With Precision Biosciences
Brief: Precision Biosciences Announces Approval Of First Clinical Trial Application Of Arcus Gene Insertion Program By Partner iECURE
Brief: Precision Biosciences Presents Late-Breaking Data Highlighting Preclinical Efficacy And Safety Of Pbgene-Hbv For Chronic Hepatitis B At Aasld’S The Liver Meeting 2023
Brief: Precision Biosciences - Extended Cash Runway Through End Of 2025
Precision BioSciences Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Precision Biosciences Presents Preclinical Data Highlighting Capabilities Of Arcus For Gene Insertion
U.S. STOCKS ON THE MOVE-Nucor, Liberty Energy, Micron Technology
U.S. STOCKS ON THE MOVE-SoundHound, Tesla, Energy firms
U.S. STOCKS ON THE MOVE-VBI Vaccine, Precision BioSciences, American Battery Technology
Precision BioSciences rises on US patent for gene editing therapy
Brief: Precision Biosciences Receives U.S. Patent Allowance Covering Pbgene-Pmm For M.3243-Associated Mitochondrial Diseases